Zobrazeno 1 - 10
of 1 017
pro vyhledávání: '"Howard I. Scher"'
Autor:
Charlotte S. Walmsley, Philip Jonsson, Michael L. Cheng, Sean McBride, Christopher Kaeser, Herbert Alberto Vargas, Vincent Laudone, Barry S. Taylor, Rajya Kappagantula, Priscilla Baez, Allison L. Richards, Anne Marie Noronha, Dilmi Perera, Michael Berger, David B. Solit, Christine A. Iacobuzio-Donahue, Howard I. Scher, Mark T. A. Donoghue, Wassim Abida, Alison M. Schram
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract Reversion mutations that restore wild-type function of the BRCA gene have been described as a key mechanism of resistance to Poly(ADP-ribose) polymerase (PARP) inhibitor therapy in BRCA-associated cancers. Here, we report a case of a patient
Externí odkaz:
https://doaj.org/article/13584368662940d8a5e228080b67724c
Autor:
Daniel Vargas P. de Almeida, Justine M. Anderson, Daniel C. Danila, Michael J. Morris, Susan F. Slovin, Wassim Abida, Erica D. Cohn, Raymond E. Baser, Howard I. Scher, Karen A. Autio
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 162-169 (2023)
Introduction: Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) during chemotherapy is associated with decreased hospitalization rates, improved quality of life, and longer survival. Limite
Externí odkaz:
https://doaj.org/article/31114f0b1c6d4458be476309142a3dfb
Autor:
Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher
Publikováno v:
European Urology Open Science, Vol 34, Iss , Pp 70-78 (2021)
Background: Phase 2 trial endpoints that can be utilized in high-risk biochemical recurrence (BCR) after prostatectomy as a way of more rapidly identifying treatments for phase 3 trials are urgently needed. The efficacy of abiraterone acetate plus pr
Externí odkaz:
https://doaj.org/article/7cb29db5a1d04ef391276d51f770d34a
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Dana W. Y. Tsui, Michael L. Cheng, Maha Shady, Julie L. Yang, Dennis Stephens, Helen Won, Preethi Srinivasan, Kety Huberman, Fanli Meng, Xiaohong Jing, Juber Patel, Maysun Hasan, Ian Johnson, Erika Gedvilaite, Brian Houck-Loomis, Nicholas D. Socci, S. Duygu Selcuklu, Venkatraman E. Seshan, Hongxin Zhang, Debyani Chakravarty, Ahmet Zehir, Ryma Benayed, Maria Arcila, Marc Ladanyi, Samuel A. Funt, Darren R. Feldman, Bob T. Li, Pedram Razavi, Jonathan Rosenberg, Dean Bajorin, Gopa Iyer, Wassim Abida, Howard I. Scher, Dana Rathkopf, Agnes Viale, Michael F. Berger, David B. Solit
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-15 (2021)
Abstract Background Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity and the fraction of circulatin
Externí odkaz:
https://doaj.org/article/a175329a098b4151983ca7a727781ce0
Autor:
David Lu, Rachel Krupa, Melissa Harvey, Ryon P. Graf, Nicole Schreiber, Ethan Barnette, Emily Carbone, Adam Jendrisak, Audrey Gill, Sarah Orr, Howard I. Scher, Joseph Daniel Schonhoft
Publikováno v:
Journal of Circulating Biomarkers, Vol 9, Iss 1, Pp 13-19 (2020)
Introduction: Here we describe the development of a protein immunofluorescent assay for the detection of nuclear-localized androgen receptor variant 7 (AR-V7) protein within circulating tumor cells (CTCs) identified in patient blood samples. Used in
Externí odkaz:
https://doaj.org/article/f2fff97879a2482492016803266e8339
Autor:
Michael R. McDevitt, Daniel L. J. Thorek, Takeshi Hashimoto, Tatsuo Gondo, Darren R. Veach, Sai Kiran Sharma, Teja Muralidhar Kalidindi, Diane S. Abou, Philip A. Watson, Bradley J. Beattie, Oskar Vilhemsson Timmermand, Sven-Erik Strand, Jason S. Lewis, Peter T. Scardino, Howard I. Scher, Hans Lilja, Steven M. Larson, David Ulmert
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Radionuclides that emit alpha particles (charged helium nuclei) are currently used clinically to treat cancers including prostate cancer. Here, the authors combine a humanized antibody to an alpha particle emitter, specifically to target a downstream
Externí odkaz:
https://doaj.org/article/02a356c6cc14425c8da1a1e7764743bc
Autor:
Kelsey E. Breen, Heather Symecko, Kelsey Spielman, Rebecca Gebert, Ibrahim H. Shah, Stacy Pundock, Melissa Batson, Vivek K. Narayan, Zsofia K. Stadler, Karen A. Autio, Wassim Abida, Daniel C. Danila, Howard I. Scher, Michael J. Morris, Jada G. Hamilton, Mark E. Robson, Susan M. Domchek, Maria I. Carlo
Publikováno v:
Journal of Urology. 209:918-927
Autor:
Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad H. Stopsack, Christoph Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Z. Mazzu, Naga Vara Kishore Pillarsetty, Gwo-Shu Mary Lee, Howard I. Scher, Michael J. Morris, Tiffany Traina, Pedram Razavi, Wassim Abida, Jeremy C. Durack, Stephen B. Solomon, Matthew G. Vander Heiden, Lorelei A. Mucci, Andreas G. Wibmer, Nikolaus Schultz, Philip W. Kantoff
Publikováno v:
Clin Cancer Res
Purpose: Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate cancer is largely unknow
Autor:
Alexander Pan, Rachel E. Reingold, Jimmy L. Zhao, Andrea Moy, Lukas Kraehenbuehl, George Dranitsaris, Sean M. McBride, Howard I. Scher, Marisa A. Kollmeier, Han Xiao, Dana E. Rathkopf, Mario E. Lacouture
Publikováno v:
J Urol
PURPOSE: Prostate cancer (PCa) patients treated with apalutamide frequently develop rash. We aim to characterize apalutamide-related dermatologic adverse events (dAE) and management. MATERIALS AND METHODS: We assessed 303 PCa patients treated with ap